B cells

[Bone Research] Using genetically modified mice and high-throughput analyses, scientists demonstrated that prolonged hypoxia-inducible factor (HIF)-1α signaling in B cells led to enhanced eceptor activator of nuclear factor kappa-Β production and osteoclast formation.

[Haematologica] Researchers studied the influence of anthropometric and body composition measurements on CAR-T-related immunotoxicity in 64 patients receiving CD19-directed CAR-T for relapsed/refractory B cell malignancies.

[EMBO Journal] Researchers revealed Pax5-Jak2 as an important nuclear driver of leukemogenesis by maintaining phosphorylated STAT5 levels in the nucleus.

[Legend Biotech Corporation] Legend Biotech Corporation achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel, a B cell maturation antigen-directed CAR-T therapy.

[Molecular Therapy] Researchers are now studying how to expand CAR T s technology beyond its use in conventional polyclonal αβ T cells to address limitations to the current therapy in cancer and applications beyond it.

[Molecular Biology Reports] Researchers assessed the suppressing effect of VGB4, a vascular endothelial growth factor (VEGF) antagonist peptide with the binding ability to both VEGF receptor1 and VEGF receptor2, on VEGF-induced proliferation and migration of the human lung adenocarcinoma cell line A549 and the human colon adenocarcinoma cell line HT29.